BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Juvenile Diabetes Research Foundation Welcomes David E. Wheadon, M.D. as New Executive Vice President of Research and Advocacy


5/8/2013 11:04:55 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 8, 2013 /PRNewswire-USNewswire/ -- JDRF announced today its new executive vice president of research and advocacy, David E. Wheadon, M.D. Dr. Wheadon brings 26 years of experience as a highly effective leader in drug development and translational research, regulatory and medical affairs, and patient advocacy. In this new position, he will work closely with JDRF's president and CEO, Jeffrey Brewer, and the senior leadership of JDRF's research and advocacy teams, overseeing all aspects of the organization's efforts to accelerate the discovery, development, and delivery of life-changing therapies for type 1 diabetes (T1D).

"After conducting an international search for candidates to fill this important new role for JDRF, we found a perfect match in Dr. Wheadon's distinguished medical and research background, his deep knowledge of the regulatory process, and his demonstrated ability to build alliances and manage teams," Mr. Brewer said.

Dr. Wheadon joins JDRF's leadership team after serving as senior vice president of scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America. There, he provided strategic leadership in setting the scientific and regulatory advocacy agenda for the biopharmaceutical industry, and built and strengthened collaborative alliances.

A graduate of Harvard College with a doctor of medicine from Johns Hopkins University, Dr. Wheadon has worked in leadership roles with major pharmaceutical companies, including: vice president of global pharmaceutical regulatory and medical sciences at Abbott Laboratories; senior vice president of U.S. regulatory affairs at GlaxoSmithKline Pharmaceuticals; and clinical research physician at Eli Lilly, where he was integral to the successful development and approval of several important drugs for central nervous system diseases, diabetes, gastrointestinal disorders, and diseases in other therapeutic areas.

Mr. Brewer continued: "Dr. Wheadon's broad exposure to industry, government, the Food and Drug Administration, academia, and influential policy and decision makersalong with his world-class research training and credentialscover all the aspects of the translational research pipeline where JDRF works today. Under his leadership, we look forward to expanding JDRF's capabilities and increasing our emphasis on exciting translational opportunities that hold the most promise to improve the lives of people with type 1 diabetes in the next decade, on our way to a future where this disease is spoken about in the past tense."

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness.

For more information, please visit jdrf.org.

SOURCE JDRF



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES